TCT 2022 | FRANCE-TAVI Registry: Small Annuli

The presence of small annuli, defined in this registry as < 23 mm diameter or indexed diameter <12 mm/m2 by CT, continues to be one of the greatest challenges of both surgical and endovascular aortic valve treatments.

TCT 2022

The FRANCE-TAVI Registry looked at 1,195 patients presenting small annuli. 895 (74.9%) received balloon expandable valves (BEV) and 300 self-expanding valves (SEV).

After adjusting with propensity score, due to population mismatch, 696 BEV and 232 SEV patients were matched.

Primary end point was permanent pacemaker implantation moderate to severe PPMI at one year. 

Mean age was 82 and EuroScore was 4.5. Ejection fraction was 60%.

The most frequent approach was femoral (close to 90%), there were no differences in predilution or in valve diameter. 

In hospital complications were low and with no differences, but the need for pacemaker implantation was higher in the SEV group (9.3% vs. 18.3% p=0.003).

Read also: Primary vs Secondary Retrograde Approach in CTO: Differences.

Primary end point resulted in favor of SEV, severe PPMI 8% vs. 3.5% (p=<0.001 and PPMI moderate or severe 38.5% vs. 15.6% p<0.001).

Mean gradient and valve area at one year were also in favor of SEV, 13.8 mmHg, vs 8.5 mmHg p=<0.001 and 1.1 cm2/m2 vs 0.9 cm2/m2.

At 3 years, mortality was higher in PPMI patients, as was the presence of atrial fibrillation. 

Read also: Is the Cause of Mitral Regurgitation Relevant for MitraClip?

The authors have concluded that SEV presented lower PPMI rate and better hemodynamic profile, in addition to PPMI being associated to higher mortality. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Transcatheter Aortic Valve Replacement in Small Aortic Annuli: Results From the FRANCE-TAVI Registry. Walid Ben-Al.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...